NeuroPace stock slipped about 3% to US$14.56 after its Q2 print, which may feel jarring given the company came into earnings with a modest gain over the past week but pressure over the past month. The headline is still about a business in loss making mode. Q1 basic earnings per share were a loss of US$0.20 on revenue of US$22.07m, and the trailing twelve months show US$99.53m in sales with ongoing losses. The real question now is how that loss profile fits against the multi year earnings and valuation story investors have been watching.

Is NeuroPace trading at a genuine discount on that 5x P/S, or is the stock already pricing in those aggressive growth forecasts? Compare the current share price to our detailed valuation analysis for…